These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15482232)

  • 21. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
    Clark JP; Langston E
    Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Telithromycin, a once-a-day ketolide in the treatment of community acquired pneumonia].
    Carbon C
    Presse Med; 2000 Dec; 29(37):2042-3. PubMed ID: 11155730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketolides in the treatment of respiratory infections.
    Zhanel GG; Hoban DJ
    Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections.
    Ciervo CA; Shi J
    Curr Med Res Opin; 2005 Oct; 21(10):1641-50. PubMed ID: 16238904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue kinetics of telithromycin, the first ketolide antibacterial.
    Muller-Serieys C; Andrews J; Vacheron F; Cantalloube C
    J Antimicrob Chemother; 2004 Feb; 53(2):149-57. PubMed ID: 14729764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
    Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
    Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
    [No Abstract]   [Full Text] [Related]  

  • 33. Telithromycin: the first ketolide antimicrobial.
    Nguyen M; Chung EP
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telithromycin: a brief review of a new ketolide antibiotic.
    Scheinfeld N
    J Drugs Dermatol; 2004; 3(4):409-13. PubMed ID: 15303785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D; Zhanel G; Hoban D
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of telithromycin in community-acquired pneumonia.
    Van Rensburg DJ; Matthews PA; Leroy B
    Curr Med Res Opin; 2002; 18(7):397-400. PubMed ID: 12487505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
    Felmingham D; Farrell DJ; Reinert RR; Morrissey I
    J Infect; 2004 Jan; 48(1):39-55. PubMed ID: 14667791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solithromycin: A novel ketolide antibiotic.
    Buege MJ; Brown JE; Aitken SL
    Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.